Evidence map›Paper›PMID 30989426›Full record

ReviewFamilial cancer2019

Hereditary gastric cancer: what's new? Update 2013-2018.

Rachel S van der Post, Carla Oliveira, Parry Guilford, Fátima Carneiro

Abstract readReview
PubMed Publisher
In one paragraph

Review in Familial cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Gastric Cancer Genetics and Its Implications for Diagnosis, Prognosis, and Treatment of the Disease.The Korean journal of helicobacter and upper gastrointestinal research · 2024
    Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Functional Study of SAMD9L in Familial Gastric Cancer.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2023
    Article
  8. Hereditary cancer syndromes.World journal of clinical oncology · 2023
    Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Cancers · 2021
    Article
  15. Genetic and Epigenetic Alterations ofPharmaceuticals (Basel, Switzerland) · 2021
    Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Rachel S van der PostDepartment of Pathology, Radboud university medical centre, Nijmegen, The Netherlands.
Carla Oliveirai3S - Instituto de Investigação e Inovação em Saúde, University of Porto, Rua Júlio Amaral de Carvalho, 45, 4200-135, Porto, Portugal.
Parry GuilfordCancer Genetics Laboratory, Department of Biochemistry, Centre for Translational Cancer Research, Te Aho Matatū, University of Otago, Dunedin, Aotearoa, New Zealand.
Fátima Carneiroi3S - Instituto de Investigação e Inovação em Saúde, University of Porto, Rua Júlio Amaral de Carvalho, 45, 4200-135, Porto, Portugal. fcarneiro@ipatimup.pt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Around 10-20% of gastric cancer patients have relatives with a diagnosis of GC and in 1-3% of patients a genetic cause can be confirmed. Histopathologically, GC is classified into intestinal-type, with glandular growth, and diffuse-type with poorly cohesive growth pattern often with signet ring cells. Familial or hereditary GC is classified into hereditary diffuse GC (HDGC), familial intestinal GC (FIGC) and polyposis forms. This review focuses on recent research findings and new concepts of hereditary GC.

Indexed as

Adenocarcinomaalpha CateninAntigens, CDCadherinsFamily HealthGene SilencingGerm-Line MutationHumansPolypsStomach NeoplasmsSyndromealpha CateninAntigens, CDCadherinsCDH1 protein, humanCTNNA1 protein, humanE-CadherinHereditary diffuse gastric cancerStomach

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.